RP-L102
Phase 2Gene therapy
Rocket PharmaceuticalsRP-L102 is one of 12 biologic programs targeting Fanconi Anemia. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Fanconi Anemia
#DrugCompanyPhaseTrials
1Danocrine
SanofiApproved
Fludara
SanofiPhase 3
Ethyol
LLegacy Health System
Approved
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Promacta
GSKPhase 2
Rituxan
RochePhase 2
Busulfex
Akero TherapeuticsPhase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 2
Rabbit ATG
NovartisPhase 2
Peripheral Blood Stem Cell
FFred Hutchinson Cancer Center
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RP-L102. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Gene therapy[2]
- Highest Phase
- Phase 2[1]
- Company